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Abstract  
Background and aims 
The economic evaluation of tobacco control policies requires the adoption of assumptions 
about the impact of changes in smoking status on health related quality of life (HRQoL). 
Estimates for such impacts are necessary for different populations. This paper aims to test 
whether smoking status has an independent effect on HRQoL over and above the effect 
derived from the increased likelihood of suffering a tobacco related disease and to 
calculate utility values for the Spanish population.     
Methods 
Using data from the Spanish Encuesta Nacional de Salud of 2011-12, we estimate 
statistical models for HRQoL as measured by the EQ-5D-5L instrument as a function of 
smoking status. We include a comprehensive set of controls for biological clinical, 
lifestyle and socioeconomic characteristics.  
Results 
Smoking status has an independent, statistically significant effect on HRQoL. However, 
the size of the effect is small. The typical smoking related disease, such as lung cancer, 
is associated with a reduction in HRQoL about 5 times larger than the difference between 
current smokers and never smokers.  
Conclusion  
Attributing substantive HRQoL gains to quitting smoking as well as accounting for the 
concomitant HRQoL gain derived from a smaller likelihood of contracting tobacco 
related diseases might lead to an overestimation of the benefits of tobacco control 
policies. Nonetheless, the relatively large drops in HRQoL associated with being 
diagnosed with diseases that might be causally linked to tobacco suggest that such 
diseases should not be omitted from the economic evaluations of tobacco control policies.  
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Smoking, health related quality of life and economic evaluation  
Introduction  
That tobacco causes disease is a long established fact. In 2012, globally 12% of all deaths 
among adults aged 30 years and over were attributed to smoking [1]. Tobacco kills around 
6 million people each year. More than 5 million of those deaths are the result of direct 
tobacco use while more than 600,000 are the result of non-smokers being exposed to 
second-hand smoke [2]. The list of health conditions for which there exists scientific 
evidence showing a causal effect is likely to continue to grow, with the latest report of 
the Surgeon General [3] adding diabetes mellitus, rheumatoid arthritis, colorectal cancer 
as well as general inflammation and impairment of the immune system to the “classical” 
group of smoking related ailments such as lung cancer, chronic obstructive pulmonary 
disease (COPD), myocardial infarction, coronary disease, or stroke. Economic 
evaluations of tobacco control policies typically account for the loss of quality of life 
associated with suffering these diseases by means of health related quality of life 
(HRQoL) indices that permit the calculation of some outcome measure of life years 
adjusted by quality. Among such measures, the Quality Adjusted Life Year (QALY) [4,5, 
21] assigns a value of one to one year of life lived full health and zero to death. A relevant 
research question, with important implications for policy, is whether smoking affects 
HRQoL over and above its effect on the likelihood of contracting disease. As Vogl et al. 
[6] have argued, smoking may induce changes in utility in individuals who are otherwise 
equal to non-smokers in terms of biological, clinical and social characteristics. Such 
changes need to be duly accounted for in cost-effectiveness, cost-utility and general return 
on investment metrics for tobacco control policies.  
The main aim of this paper is to find out whether the smoking status of the general Spanish 
population is associated with systematic variations in HRQoL as measured by the EQ-
5D-5L valuation questionnaire instrument [7,8] once biological and clinical conditions 
are controlled for. 
The EQ-5D-5L questionnaire is a descriptive system of health-related quality of life 
assessing five dimensions (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression). For each of these dimensions respondents can report five levels of 
severity (no problems/slight problems/moderate problems/severe problems/extreme 
problems). The resulting 55 potential states are mapped into a one dimensional index, 
known as the EQ-5D-5L “score” or “tariff”, usually ranging between unity (representing 
the best possible outcome of “no problems” in all five dimensions) and zero (worst 
possible outcome) [22].   
 
The focus on this HRQoL instrument relates to its widespread use in economic 
evaluations of tobacco control policies [9-12]. While there are previous studies using 
Spanish data [13-16], these use the Short Form 36 (SF-36)1 instrument on a small sample 
or do not control for comorbidities. To our knowledge, there is only one cost-utility 
analysis relating to smoking and quality of life for the Spanish population [16]. Moreover, 
while these and other international studies document differences in HRQoL by smoking 
status, they do not control exhaustively for clinical conditions potentially correlated with 
tobacco consumption so it is difficult to attribute an independent effect on HRQoL to 
smoking. In contrast, our use of the Spanish National Health Survey, consisting of a 
sample of 20956 individuals and reporting a wide array of clinical conditions, offers the 
possibility of testing for the existence of such independent effects with some degree of 
confidence.  
 
Data and methods 
Our data source is the latest National Health Survey release, that of year 2011-12 [17]. 
The Spain National Health Survey (ENS) 2011-2012 is a cross sectional survey of the 
non-institutionalized Spanish population containing information on lifestyles, health and 
socioeconomic characteristics of individuals with separate adults (16+) and children 
samples. The analysis in this paper is based on the adult sample, which contains 20956 
individuals representing a population of 38.6 million. The ENS2011-12 is the first ENS 
that contains information on the EQ-5D-5L self-report questionnaire [7,8].  
 Table 1 presents a comprehensive set of descriptive statistics, including the sample size 
and equivalent number of individuals in the population broken down by gender and 5 
years age brackets. Aside from the contents of Table 1, Figure 1, presenting smoking 
                                                          
1 The Short Form-36 (SF-36) questionnaire is an established and also widely used 
health-related quality of life measure (HRQoL) [23]. It comprises eight health domains 
including ‘physical functioning’ [23]. 
status broken down by age (in bands of 5 years) and gender, shows the striking differences 
in smoking patterns among men and women in Spain. For cohorts up to 50 years of age, 
the fraction of never smokers drops gradually down to 35% for males and 45% for 
females. For older cohorts, though, the fraction of women who have never smoked 
increases sharply and reaches nearly 100% among those above 75. In contrast, less than 
45% of men above 50 report never to have smoked. These patterns reflect the gender time 
lag in the spread of the smoking epidemic in Spain, whereby smoking was rare among 
women before the 1970’s. Nonetheless, the proportion of current smokers is greater 
among men in all cohorts, even if the difference is small among those below 20 years 
(25% males and 23% females). The proportion of former smokers is ever greater for older 
cohorts among males. Indeed, for male cohorts above 50 former smokers outnumber 
never smokers or current smokers. Among cohorts of women above 50, both current 
smokers and former smokers are rare, again reflecting the fact that the smoking uptake 
was infrequent in these population subgroups.  
Figures 2 and 3 present, respectively, the average EQ-5D-5L score broken down by age, 
smoking status and gender and the proportion of individuals reporting the maximum score 
(i.e. reporting “no problems” in all five health dimensions) using the same breakdown. 
As expected, both the average score and the proportion of cases reporting no problems 
declines with age for both men and women. However, irrespective of smoking status, 
men report both higher average scores and higher proportions of maximum scores at all 
ages.  
Concerning the relationship between smoking status and the EQ-5D-5L score conditional 
on age and gender, and focusing first on males, figures 2 and 3 suggest  that among male 
cohorts up to 60 years of age, current smokers tend to report lower scores than either 
never smokers or former smokers. From 60 years onwards, it is former smokers who 
appear to report lower scores than the other two groups. As for females, current smokers 
also tend to report lower scores up to 50 years of age. From such age onwards no clear 
pattern is discernible from these figures.  
Table 1 shows rates of exposure to second hand smoke, which tend to be higher among 
the younger cohorts. Additionally Table 1 presents rates of reports of diagnosed health 
conditions associated with tobacco consumption broken down by age and gender. These 
rates show a clear association with age for both men and women. Reports of infarction or 
other heart disease diagnoses range between 1% and 26%. Those of COPD between 0% 
and 6%. Those of tumors between 0% and 8%. Table 1 also presents rates of reports of 
pain from any of these causes: migraine, back pain, arthritis or recent injuries, which 
range between 12% and 54% for males and 15% and 78% for females. Likewise, it 
includes rates of reports of diagnoses of any disease from the following list: hypertension, 
varicous veins, allergy, diabetes, stomach ulcer, urinary incontinence, high cholesterol, 
cataracts, skin problems, constipation, liver cirrhosis, hemorrhoids, osteoporosis, thyroid 
problems, menopausal problems (for women) and prostate problems (for men). These 
rates range between 20% and 83% for men and 22% and 92% for women.     
 
Our statistical analysis hinges on the specification of models that aim to explain the 
variation in the EQ-5D-5L score as a function of biological and clinical characteristic and 
lifestyles. These models need to account for the high proportion of responses reporting 
either the maximum possible value for the EQ-5D-5L score or very close to it. Similarly, 
the differences between males and females discussed above call for a separate analysis 
for both genders. Among the various statistical alternatives suggested in the literature we 
opt for the Two Part Model (TPM) [19]. The first part of the model estimates the 
probability of reporting the maximum score (i.e. no health problems in any of the 5 
domains) by means of a Probit Model. The second part explains the expectation of the 
score given that some health problem has been reported by means of a Generalized Linear 
Model (GLM) with a logarithmic link and gamma disturbances. The TPM has been shown 
to produce good results in terms of predictive power in comparison with other models in 
the context of the EQ-5D-5L [19]. Also, the TPM is readily interpretable. As mentioned 
above the first part serves to predict the probability of reporting no health problems 
(which below will be referred to as P(no health problems reported)) and the second part 
serves to predict the expected value for the tariff conditional on reporting a health 
problem, denoted as E(score| some health problem reported) below.  
With regard to the explanatory variables, we use 6 different specifications or models. Our 
baseline specification, Model 0, contains indicators for smoking status distinguishing 
between current smokers, former smokers and never smokers, a quadratic polynomial in 
age and controls for marital status, levels of alcohol consumption, physical activity, body 
mass index and an indicator for exposure to second hand smoke. Models 1 to 4 add 
alternative sets of explanatory variables to the baseline specification. Namely, Model 1 
includes indicators for medical diagnoses of each of the following conditions: heart 
infarction, malignant tumor, coronary obstructive pulmonary disease (COPD), stroke, 
other heart diseases and asthma (five of the classical tobacco related diseases). Model 2 
includes indicators for each of the following mental disorders: depression, anxiety or 
other mental problems. Model 3 includes indicators for each of the following pain 
conditions: migraine, back pain, arthritis and recent injuries. Model 4 contains indicators 
for each of the following other medical diagnoses :hypertension, varicous veins, allergy, 
diabetes, stomach ulcer, urinary incontinence, high cholesterol, cataracts, skin problems, 
constipation, liver cirrhosis, hemorrhoids, osteoporosis, thyroid problems, menopausal 
problems (for women), prostate problems (for men). Finally, the full specification, Model 
5, adds all the indicators used in Models 1, 2, 3 and 4 to the baseline specification. 
The rationale behind these specifications was the necessity to test whether any systematic 
association of smoking status with HRQoL is robust to the inclusion of different sets of 
clinical conditions. In the case of specifications 2 and 3, which add, respectively, mental 
problems and pain, the test is particularly demanding, in the sense that two of the EQ-5D-
5L domains are precisely mental problems and pain. Of course, in the context of a cross 
section of non-experimental observational data we cannot rule out that such effects, if 
they exist, are due to correlated unobservables. In order to explore this possibility we 
carry out a robustness check consisting in expanding specification 5 with controls for 
social class and degree of perceived social capital.   
From these two components it is possible to retrieve the predictions for the unconditional 
expectation of the score, simply as:  
E(score)=P(no health problems reported)*value of maximum score+(1-( P(no health 
problems reported)*E(score| some health problem reported). 
These unconditional expectations, and their conditional (on reporting some health 
problem) counterparts, i.e. E(score| some health problem reported), may be used to 
produce estimates for the EQ-5D-5L based HRQoL index of prototypical profiles of 
individuals by gender, smoking status and age to use in cost-utility analysis of tobacco 
policies.   
 
Results 
Table 2 presents the estimates for the marginal effects of smoking status on HRQoL 
within the TPM for the models described above, along with the Akaike Information 
Criterion (AIC) measure of goodness of fit.  The top panel corresponds to Part 1 of the 
TPM, that is, the probability of reporting no health problems in any of the EQ-5D-5L 
domains, while the bottom panel corresponds to the second part of the TPM, i.e. the model 
for expected value of the score conditional on reporting some health problem. The omitted 
category within the smoking status set of dummy variables is “never smoker”.  
For the first part of the TPM, note that the best specification in terms of the AIC statistic 
is the one containing the full set of explanatory variables (Model 5), both for males and 
females. Among Models 1-4, which add alternative sets of covariates to the baseline 
specification in Model 0, the one including pain conditions (Model 4) results in the best 
improvement in goodness of fit with respect to the baseline specification, followed by the 
model including mental diseases (Model 2). This is not surprising since mental disorders 
and pain are two of the dimensions along which the EQ-5D-5L is measured. The inclusion 
of tobacco related diseases (Model 1) improves the AIC with respect to the baseline 
specification by smaller margins.   
The marginal effect of current smoking on the probability of reporting some health 
problem among both males and females ranges between 4% and 2%, this latter estimate 
corresponding to the best performing model (Model 5), which in the case of women 
verges on statistical insignificance (p value=0.109). As for the marginal effect of former 
smoking, it ranges between 5% in the baseline specification and statistical insignificance 
for both men and women in Model 5.  
For the second part of the TPM2, and in the case of males, Models 1 to 4 yield no clear 
improvements in the AIC with respect to the baseline specification. And, although Model 
5 yields a better AIC, the marginal effects of the smoking status variables are not 
significant. For females, the baseline specification yields similar AIC statistics than the 
rest of specifications, with a significant but small (about -0.02 EQ-5D-5L score points) 
                                                          
2 The estimation of the second part of the model uses a smaller number of observations than the 
estimation for the first part. As reflected in Table 1, the sample sizes are 2770 for men and 5117 for 
women. However these samples contain variation in smoking status: among males there are 952 never 
smokers, 796 current smokers and 1022 former smokers and among women the corresponding figures 
are 3729, 845 and 543. 
marginal effect for being a former smoker. These results are robust to the inclusion of 
controls for social class and degree of perceived social support. 
Table 3 presents estimates for the expected EQ-5D-5L score for a set of representative 
profiles broken down by age, gender and smoking status. These estimates are defined as 
the unconditional expectation of the score over the relevant population group, and they 
have been calculated with the two parts of Model 5. Note that, within age and gender 
categories, there are no stark differences in the expected EQ-5D-5L score by smoking 
status.  
Finally, Table 4 presents estimates for the change in the score associated with suffering a 
tobacco related disease. They are defined as the difference between the unconditional 
expectation of the HRQoL score over the population of individuals who do not suffer any 
of the diseases minus the expectation of the HRQoL conditioned on suffering the 
corresponding disease and reporting health problems for the same population. Note that 
for some diseases this change is very substantial For instance, the drop in the tariff reaches 
about 0.35 score points in the case of stroke.   
 
Discussion  
The conjunction of results presented above suggests a series of stylized facts about the 
relationship between smoking and HRQoL as measured by the EQ-5D-5L. First, even the 
most comprehensive specifications in terms of clinical, biological and lifestyle conditions 
detect an independent effect of smoking on HRQoL in comparison to otherwise equal 
never smokers. This effect operates through a larger probability of reporting some health 
problem, but not through current smokers reporting a lower score than otherwise equal 
never smokers who also report health problems along any of the EQ-5D-5L dimensions.  
We find that being a former smoker also seems to affect the probability of reporting health 
problems, but its effect is not statistically significant once the full set of available reported 
clinical diagnoses is included. This suggests that the former smoker status is a proxy for 
clinical diagnoses. In the case of women, though, we find that being a former smoker has 
a small and significant negative effect on the expected EQ-5D-5L score among those who 
report a health problem. This gender effect is probably a result of the differences in the 
evolution of the smoking epidemic in Spain, where for male former smokers the average 
period since quitting is longer than for female former smokers (for instance, the 
proportion of male former smokers who quit more than 10 years before the date of the 
survey is 56% while the corresponding figure for females is 42.4%) [17]. 
Nonetheless, the effects of smoking on HRQoL are very small in magnitude once clinical 
conditions are comprehensively controlled for. For instance, currently smoking women 
in the 45-54 age band are expected to have a EQ-5D-5L score of 0.89 compared to a score 
of 0.92 for women in the same age band who have never smoked or 0.91 for former 
smokers.  
In contrast, the substantive damaging effect of smoking operates through the reduction in 
HRQoL associated with suffering a smoking related disease. For instance, having a stroke 
reduces the EQ-5D-5L score by a margin more than ten times larger than the difference 
between current and never smokers mentioned above. For those that suffer a heart 
infarction, other heart diseases, COPD or a tumor the margin is about 5 times larger, and 
for asthma the difference is about 3 times larger.  
Conclusion  
We have estimated econometric models for the EQ-5D-5L score in the Spanish 
population as a function of smoking status plus a wide range of clinical indicators with a 
view to separating the effect of smoking status from the effect of concomitant diseases 
potentially triggered by tobacco consumption. The results that we have discussed above 
are limited by the fact that the observational nature of the data does not afford a study 
design able to retrieve causal effects. On the other hand, they are based on a particular 
representation of HRQoL, the EQ-5D-5L, and could well be different using other health 
instruments. In this respect, as the authors of the EQ-5D-5L Index have warned, the value 
set obtained might be subject to revision due to changes in the EuroQol protocol [20]. 
These shortcomings call for further research with more sophisticated datasets and 
alternative health instruments.  
Notwithstanding these caveats, there are two stark implications from our results for 
research on the cost-effectiveness, the cost-utility and the return on investment in general 
of tobacco control policies. Firstly, attributing substantive HRQoL gains to quitting 
smoking as well as accounting for the concomitant HRQoL gain derived from a smaller 
likelihood of contracting tobacco related diseases might lead to an overestimation of the 
benefits of tobacco control policies. And, second, but not least, the relatively large drops 
in HRQoL associated with being diagnosed with diseases that might be causally linked 
to tobacco suggest that they should not be omitted from the economic evaluations of 
tobacco control policies. For instance, a diagnosis of either arthritis or diabetes, two 
diseases causally associated with smoking according to the latest report from the Surgeon 
General [3], but nonetheless typically omitted in economic evaluation of tobacco policy, 
are associated with a reduction of about 0.15 in HRQoL as measured by the EQ-5D-5L 
score. This effect is about 5 times larger than the difference between smoking currently 
and not having smoker ever for women in the 45-54 age band. New economic evaluation 
research in the area of tobacco should consider the inclusion of such diseases.  
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Table 2 Marginal effect estimates for smoking status in Two Part Models. Omitted category: never smoker.  
  Part 1: Prob (No health problems reported)  
   Probit Model  
  MEN (N=9619) WOMEN (N=11337) 
  
Model 0 Model 1 Model 2 Model 3 Model 4 Model 5 Model 0 Model 1 Model 2 Model 3 Model 4 Model 5 
CURRENT  -0,0379*** -0,0327** -0,0260* -0,0350*** -0,0364*** -0,0212** -0,0409*** -0,0347** -0,0262* -0,0344** -0,0491*** -0,0198* 
FORMER -0,0531*** -0,0282** -0,0400*** -0,0348*** -0,0306*** -0,0110 -0,0452*** -0,0361** -0,0445*** -0,0263* -0,0436*** -0,0196 
AIC 1.044 1.014 .9773 1.006 .929 .866 1.133 1.111 1.028 1.062 .9795 .9038 
    
  Part 2: E(Score | Some health problem reported)  
   Generalized linear model  
  MEN (N=2770) WOMEN (N=5117) 
  
Model 0 Model 1 Model 2 Model 3 Model 4 Model 5 Model 0 Model 1 Model 2 Model 3 Model 4 Model 5 
CURRENT  0,0010 0,0027 0,0058 0,0008 0,0008 0,0061 -0,0124 -0,0105 -0,0076 -0,0143* -0,0151 -0,0092 
FORMER -0,0088 -0,0034 -0,0070 -0,0094 -0,0045 -0,0023 -0,0215** -0,0170* -0,0266*** -0,0190** -0,0252** -0,0204** 
AIC 1.529 1.531 1.526 1.535 1.530 1.382 1.382 1.380 1.370 1.381 1.379 1.375 
* denote p values between 0.05 -0.1; **denote p values between 0.01-0.05; ***denote p values below 0.01 
 
  
Table 3 Estimates for the unconditional expectation of the EQ-5D-5L score by age, gender and smoking status, with bootstrapped standard 
errors 
 Men 
Status/age band 15-24 25-34 35-44 45-54 55-64 65-74 75-84 
Current smokers 0,951 0,953 0,949 0,931 0,921 0,899 0,834 
 0,041 0,021 0,017 0,016 0,021 0,029 0,04 
Former smokers 0,971 0,962 0,959 0,941 0,915 0,896 0,816 
 0,055 0,035 0,025 0,022 0,023 0,019 0,04 
Never smokers 0,964 0,967 0,962 0,948 0,922 0,916 0,83 
  0,04 0,033 0,017 0,021 0,021 0,024 0,023 
  Women  
Status/age band 15-24 25-34 35-44 45-54 55-64 65-74 75-84 
Current smokers 0,947 0,938 0,929 0,896 0,873 0,822 0,77 
 0,03 0,019 0,016 0,015 0,02 0,03 0,051 
Former smokers 0,965 0,953 0,948 0,916 0,85 0,818 0,662 
 0,039 0,033 0,018 0,019 0,022 0,026 0,043 
Never smokers 0,965 0,963 0,948 0,92 0,855 0,791 0,672 
  0,027 0,015 0,014 0,014 0,013 0,01 0,011 
 
  
Table 4  Decrement in EQ-5D-5L score associated with reporting a diagnosis of a smoking related disease, with bootstrapped standard errors. 
 Men Women 
COPD -0.159 -0.144 
 0.022 0.021 
Stroke -0.356 -0.367 
 0.047 0.049 
Heart infarction -0.176 -0.152 
  0.029 0.04 
Other heart disease -0.159 -0.165 
 0.02 0.019 
Tumor -0.194 -0.139 
 0.032 0.022 
Arthritis -0.201 -0.192 
 0.015 0.02 
Diabetes -0.192 -0.141 
 0.02 0.012 
 
  
  
 
  
 
  
 
 
